iangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medicine packing materials.
Hengrui Medicine, founded in April, 1997 and headquartered in Lianyungang, is an innovative pharmaceutical developer. The founder is Zhou Yunshu. Listed on the SSE on October 18, 2000, the company's major shareholders are Jiangsu Hengrui Pharmaceutical Group Co., Ltd., Tibet Dayuan Enterprise Management Co., Ltd. and Hong Kong Securities Clearing Co., Ltd.. Rivals that have direct and indirect competition with Hengrui Medicine include Harbin Pharmaceutical, Yunnan Baiyao, Glaxo Smith Kline, Pfizer, etc.
Declaration of the first affordable rental housing REITs
Harbin housing and Urban Rural Development Bureau organized and held a working meeting on handling the risk of overdue delivery and uncompleted tail of Evergrande real estate project
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Linyang energy: the holding subsidiary won the bid for the 274 million yuan energy storage equipment procurement project
Heavy Pharmaceutical Holdings: heavy Pharmaceutical Co., Ltd. plans to provide financial assistance of 57.72 million yuan to heavy pharmaceutical Jiulong
2022 China AI Health 30 Report
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Hengrui medicine: ω- 3. Fatty acid ethyl ester 90 soft capsule has obtained the drug registration certificate
Four European gas buyers have bought gas in rubles.
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
State Intellectual Property Office: crack down on "porcelain touch" rights protection and promote balanced protection
361 degrees announced that the retail sales of main brand products in the first quarter recorded a high double-digit growth year-on-year.
Heilongjiang Provincial Department of culture and Tourism: arrange at least 200 million funds to support the development of ice and snow industry every year
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Defining key tasks and accelerating the construction of new urbanization
Daodaoquan: Chongqing subsidiary plans to apply to the bank for a credit line of 160 million yuan
The 14th five year development plan of Shenzhen national high tech Zone aims to reach 200 listed enterprises in the zone by 2025
Industrial Securities: the duration of the employee stock ownership plan will expire on August 17